Key Takeaways
- Citigroup’s Geoff Meacham established a Wall Street-leading $1,600 price target for LLY, suggesting 45% potential upside.
- Berenberg moved LLY to Buy from Hold with a new $1,400 price target, forecasting approximately 25% gains.
- Shares of LLY traded at $1,138, marking a 2% increase during Tuesday’s session.
- The pharmaceutical giant commands a 60% share of the global weight-loss medication market, generating $14.9 billion in quarterly revenue from obesity and diabetes therapies.
- Wall Street consensus shows 20 analysts rating LLY as a Strong Buy, with an average target price of $1,375.78.
Eli Lilly shares are drawing significant Wall Street attention following back-to-back analyst upgrades released within a single day.
Citigroup’s Geoff Meacham established a $1,600 valuation target for LLY, representing the most aggressive forecast among major financial institutions. This projection suggests approximately 45% appreciation potential from the stock’s present trading level of $1,138.
Meacham, who holds a five-star analyst ranking and maintains a 59% accuracy record, reaffirmed his Buy recommendation while establishing the new target. His optimistic outlook centers on Eli Lilly’s commanding position within the weight-loss pharmaceutical sector.
The Indianapolis-based drugmaker controls 60% of the worldwide weight-loss medication market. Zepbound and Mounjaro, its flagship obesity and diabetes therapies, are producing combined quarterly revenues of $14.9 billion.
Meacham also observed that LLY shares have declined 8% during the previous month, characterizing this pullback as an attractive entry point for long-term investors.
Berenberg Shifts to Bullish Stance
Berenberg elevated LLY from Hold to Buy on Tuesday while increasing its valuation target to $1,400 from $1,220. The investment firm anticipates approximately 25% appreciation from present price levels.
Berenberg stated that its 2026 return on research investment framework validates Eli Lilly’s history of producing industry-leading shareholder returns. The firm also projects the pharmaceutical company will surpass its fiscal 2026 outlook.
The research note identified an approaching catalyst: anticipated diabetes regulatory approval for Foundayo, Eli Lilly’s oral GLP-1 therapy. Foundayo generated approximately $100 million in Q2 2026 revenue, with acceleration anticipated following complete regulatory clearance.
Berenberg further emphasized Eli Lilly’s strategic pipeline development, observing that numerous emerging assets possess multibillion-dollar revenue possibilities. The corporation has allocated roughly $60 billion across more than 25 strategic transactions and partnerships year to date.
Broad Analyst Support Continues
Wall Street consensus reflects a Strong Buy recommendation for LLY from 20 sell-side analysts. The ratings distribution includes 18 Buy recommendations and two Hold ratings. The mean price objective across all analysts stands at $1,375.78, indicating roughly 12% upside potential from current trading levels.
BMO Capital and JPMorgan have both recently reaffirmed favorable views on LLY. Each institution maintains a $1,400 valuation target, emphasizing expansion within the incretin therapeutic category.
Eli Lilly’s fundamental metrics support the optimistic analyst sentiment. The organization reported nearly 50% year-over-year revenue expansion over the trailing twelve months and maintains a flawless Piotroski Score of 9.
The Medicare Bridge initiative is additionally fueling heightened demand for Eli Lilly’s obesity medications, according to Berenberg’s analysis.
Competitor Novo Nordisk, which maintains a 38% global obesity drug market share, recently unveiled a corporate rebrand, transitioning to the simplified name “Novo.” The Danish pharmaceutical firm is scheduled to present a comprehensive strategic roadmap at its Capital Markets Day event on September 21.
Eli Lilly has also announced plans to acquire Merida Biosciences for approximately $2.875 billion in cash, aimed at bolstering its autoimmune and allergic disease treatment portfolio.
LLY closed Tuesday’s trading session at $1,138.28, gaining $22.58, representing a 2.02% advance for the day.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
